Chengdu’s HitGen announced a drug discovery collaboration with Boehringer Ingelheim, using HitGen’s DNA-coded library of 90 billion leads. The latest HitGen collaboration will identify novel small molecule leads for “targets of interest to Boehringer Ingelheim,” though no further details were provided. All together, HitGen has disclosed eight collaborations with other pharmas in the last two years. Each one is built on a financial structure of upfront payments plus milestones, though no specific financial information is disclosed.
Source: China Biotoday
